@article{RymaTylekLiebscheretal.2021,
  author    = {Ryma, Matthias and Tylek, Tina and Liebscher, Julia and Blum, Carina and Fernandez, Robin and B{\"o}hm, Christoph and Kastenm{\"u}ller, Wolfgang and Gasteiger, Georg and Groll, J{\"u}rgen},
  title     = {Translation of collagen ultrastructure to biomaterial fabrication for material-independent but highly efficient topographic immunomodulation},
  series = {Advanced materials},
  volume    = {33},
  journal   = {Advanced materials},
  number    = {33},
  doi       = {10.1002/adma.202101228},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-256381},
  year      = {2021},
  abstract  = {Supplement-free induction of cellular differentiation and polarization solely through the topography of materials is an auspicious strategy but has so far significantly lagged behind the efficiency and intensity of media-supplementation-based protocols. Consistent with the idea that 3D structural motifs in the extracellular matrix possess immunomodulatory capacity as part of the natural healing process, it is found in this study that human-monocyte-derived macrophages show a strong M2a-like prohealing polarization when cultured on type I rat-tail collagen fibers but not on collagen I films. Therefore, it is hypothesized that highly aligned nanofibrils also of synthetic polymers, if packed into larger bundles in 3D topographical biomimetic similarity to native collagen I, would induce a localized macrophage polarization. For the automated fabrication of such bundles in a 3D printing manner, the strategy of "melt electrofibrillation" is pioneered by the integration of flow-directed polymer phase separation into melt electrowriting and subsequent selective dissolution of the matrix polymer postprocessing. This process yields nanofiber bundles with a remarkable structural similarity to native collagen I fibers, particularly for medical-grade poly(ε-caprolactone). These biomimetic fibrillar structures indeed induce a pronounced elongation of human-monocyte-derived macrophages and unprecedentedly trigger their M2-like polarization similar in efficacy as interleukin-4 treatment.},
  language  = {en}
}
@article{MoratinIckrathScherzadetal.2021,
  author    = {Moratin, Helena and Ickrath, Pascal and Scherzad, Agmal and Meyer, Till Jasper and Naczenski, Sebastian and Hagen, Rudolf and Hackenberg, Stephan},
  title     = {Investigation of the immune modulatory potential of zinc oxide nanoparticles in human lymphocytes},
  series = {Nanomaterials},
  volume    = {11},
  journal   = {Nanomaterials},
  number    = {3},
  issn      = {2079-4991},
  doi       = {10.3390/nano11030629},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-234016},
  year      = {2021},
  abstract  = {Zinc oxide nanoparticles (ZnO-NP) are commonly used for a variety of applications in everyday life. In addition, due to its versatility, nanotechnology supports promising approaches in the medical sector. NP can act as drug-carriers in the context of targeted chemo- or immunotherapy, and might also exhibit autonomous immune-modulatory characteristics. Knowledge of potential immunosuppressive or stimulating effects of NP is indispensable for the safety of consumers as well as patients. In this study, primary human peripheral blood lymphocytes of 9 donors were treated with different sub-cytotoxic concentrations of ZnO-NP for the duration of 1, 2, or 3 days. Flow cytometry was performed to investigate changes in the activation profile and the proportion of T cell subpopulations. ZnO-NP applied in this study did not induce any significant alterations in the examined markers, indicating their lack of impairment in terms of immune modulation. However, physicochemical characteristics exert a major influence on NP-associated bioactivity. To allow a precise simulation of the complex molecular processes of immune modulation, a physiological model including the different components of an immune response is needed.},
  language  = {en}
}
@article{GrohBerveMartini2021,
  author    = {Groh, Janos and Berve, Kristina and Martini, Rudolf},
  title     = {Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset},
  series = {Brain Communications},
  volume    = {3},
  journal   = {Brain Communications},
  number    = {2},
  doi       = {10.1093/braincomms/fcab047},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260167},
  year      = {2021},
  abstract  = {Targeting neuroinflammation in models for infantile and juvenile forms of neuronal ceroid lipofuscinosis (NCL, CLN disease) with the clinically established immunomodulators fingolimod and teriflunomide significantly attenuates the neurodegenerative phenotype when applied preventively, i.e. before the development of substantial neural damage and clinical symptoms. Here, we show that in a mouse model for the early onset and rapidly progressing CLN1 form, more complex clinical phenotypes like disturbed motor coordination and impaired visual acuity are also ameliorated by immunomodulation. Moreover, we show that the disease outcome can be attenuated even when fingolimod and teriflunomide treatment starts after disease onset, i.e. when neurodegeneration is ongoing and clinical symptoms are detectable. In detail, treatment with either drug led to a reduction in T-cell numbers and microgliosis in the CNS, although not to the same extent as upon preventive treatment. Pharmacological immunomodulation was accompanied by a reduction of axonal damage, neuron loss and astrogliosis in the retinotectal system and by reduced brain atrophy. Accordingly, the frequency of myoclonic jerks and disturbed motor coordination were attenuated. Overall, disease alleviation was remarkably substantial upon therapeutic treatment with both drugs, although less robust than upon preventive treatment. To test the relevance of putative immune-independent mechanisms of action in this model, we treated CLN1 mice lacking mature T- and B-lymphocytes. Immunodeficient CLN1 mice showed, as previously reported, an improved neurological phenotype in comparison with genuine CLN1 mice which could not be further alleviated by either of the drugs, reflecting a predominantly immune-related therapeutic mechanism of action. The present study supports and strengthens our previous view that repurposing clinically approved immunomodulators may alleviate the course of CLN1 disease in human patients, even though diagnosis usually occurs when symptoms have already emerged.},
  language  = {en}
}